JP2012503665A - アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法 - Google Patents

アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法 Download PDF

Info

Publication number
JP2012503665A
JP2012503665A JP2011529177A JP2011529177A JP2012503665A JP 2012503665 A JP2012503665 A JP 2012503665A JP 2011529177 A JP2011529177 A JP 2011529177A JP 2011529177 A JP2011529177 A JP 2011529177A JP 2012503665 A JP2012503665 A JP 2012503665A
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
solid oral
aliskiren
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011529177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012503665A5 (enExample
Inventor
ゴシュ，インドラジト
コワルスキ，ジェームズ
スナイダー，ジェニファー
トン，ウエィ−キン
ビッパグンタ，スダ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012503665A publication Critical patent/JP2012503665A/ja
Publication of JP2012503665A5 publication Critical patent/JP2012503665A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011529177A 2008-09-24 2009-09-23 アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法 Pending JP2012503665A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9959508P 2008-09-24 2008-09-24
US61/099,595 2008-09-24
US16179909P 2009-03-20 2009-03-20
US61/161,799 2009-03-20
PCT/US2009/057993 WO2010036686A1 (en) 2008-09-24 2009-09-23 Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation

Publications (2)

Publication Number Publication Date
JP2012503665A true JP2012503665A (ja) 2012-02-09
JP2012503665A5 JP2012503665A5 (enExample) 2012-11-08

Family

ID=41323516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529177A Pending JP2012503665A (ja) 2008-09-24 2009-09-23 アリスキレンを含むガレヌス製剤および溶融押出し造粒によるその調製方法

Country Status (19)

Country Link
US (1) US20110177166A1 (enExample)
EP (1) EP2328562A1 (enExample)
JP (1) JP2012503665A (enExample)
KR (1) KR20110063684A (enExample)
CN (1) CN102164584A (enExample)
AR (1) AR073651A1 (enExample)
AU (1) AU2009296718A1 (enExample)
BR (1) BRPI0919077A2 (enExample)
CA (1) CA2736259A1 (enExample)
CL (1) CL2011000614A1 (enExample)
CO (1) CO6351712A2 (enExample)
EC (1) ECSP11010998A (enExample)
MA (1) MA32722B1 (enExample)
MX (1) MX2011003077A (enExample)
PE (1) PE20110925A1 (enExample)
RU (1) RU2011116122A (enExample)
TW (1) TW201016210A (enExample)
WO (1) WO2010036686A1 (enExample)
ZA (1) ZA201101686B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021020914A (ja) * 2013-03-01 2021-02-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2023539779A (ja) * 2020-09-04 2023-09-19 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有飽和複素環化合物の使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348452A (zh) * 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
EP2382967A1 (de) * 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529456A (ja) * 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 有機化合物のガレヌス製剤
JP2008510764A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト 湿気感受性薬剤の溶融顆粒を含む即時放出型組成物およびその製造法
WO2008061622A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2009040427A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
EP2062874B1 (en) * 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529456A (ja) * 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 有機化合物のガレヌス製剤
JP2008510764A (ja) * 2004-08-27 2008-04-10 ノバルティス アクチエンゲゼルシャフト 湿気感受性薬剤の溶融顆粒を含む即時放出型組成物およびその製造法
WO2008061622A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5012000944; ＡＺＩＺＩ　Ｍ: 'ＰＨＡＲＭＡＣＯＬＯＧＩＣ　ＤＥＭＯＮＳＴＲＡＴＩＯＮ　ＯＦ　ＴＨＥ　ＳＹＮＥＲＧＩＳＴＩＣ　ＥＦＦＥＣＴＳ　ＯＦ　Ａ　ＣＯＭＢＩＮＡＴＩＯＮ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＯＦ　ＮＥＰＨＲＯＬＯＧＹ Ｖ１５　Ｎ１２, 20041201, Ｐ３１２６-３１３３, ＷＩＬＬＩＡＭＳ　ＡＮＤ　ＷＩＬＫＩＮＳ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021020914A (ja) * 2013-03-01 2021-02-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP7189185B2 (ja) 2013-03-01 2022-12-13 インサイト・ホールディングス・コーポレイション ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2023539779A (ja) * 2020-09-04 2023-09-19 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有飽和複素環化合物の使用
JP7579967B2 (ja) 2020-09-04 2024-11-08 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有飽和複素環化合物の使用

Also Published As

Publication number Publication date
MA32722B1 (fr) 2011-10-02
US20110177166A1 (en) 2011-07-21
BRPI0919077A2 (pt) 2015-12-15
RU2011116122A (ru) 2012-10-27
AR073651A1 (es) 2010-11-24
CL2011000614A1 (es) 2011-11-04
MX2011003077A (es) 2011-08-03
CN102164584A (zh) 2011-08-24
WO2010036686A1 (en) 2010-04-01
AU2009296718A1 (en) 2010-04-01
ECSP11010998A (es) 2011-06-30
PE20110925A1 (es) 2012-01-13
EP2328562A1 (en) 2011-06-08
CO6351712A2 (es) 2011-12-20
KR20110063684A (ko) 2011-06-13
ZA201101686B (en) 2012-01-25
CA2736259A1 (en) 2010-04-01
TW201016210A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
AU2008309058B2 (en) Galenical formulations of Aliskiren and Valsartan
CN1997354B (zh) 有机化合物的盖仑制剂
CN1921840A (zh) 多层片剂
HK1209337A1 (en) Medicament-containing hollow particle
WO2019073477A1 (en) PHARMACEUTICAL COMPOSITION OF APREMILAST WITH EXTENDED RELEASE
CN1744889A (zh) 坦洛新的控释药物组合物
WO2008068731A1 (en) Extended release formulations of carvedilol
WO2021107967A1 (en) Pharmaceutical compositions of lurasidone
JP2013253093A (ja) ローラーコンパクターを使用した多微粒子の製造方法
US20110177166A1 (en) Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation
EA030982B1 (ru) Твердая галеновая форма с высоким содержанием фексофенадина и способ ее получения
JP2015091830A (ja) 有機化合物のガレヌス製剤
TWI436760B (zh) 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物
TWI745598B (zh) 非布司他控釋組合物及其製備方法
RU2723255C2 (ru) Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
US20110028526A1 (en) Valsartan solid oral dosage forms and methods of making such formulations
HK40008441A (en) Medicament-containing hollow particle
JP2012520895A (ja) バルサルタンおよびアリスキレンの一定用量の組合せのガレヌス製剤
HK40008438A (en) Medicament-containing hollow particle

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140507